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Abstract 
Introduction: Non-invasive ventilation (NIV) is recommended for treatment of acute hypercapnic 
respiratory failure (AHRF) refractory to medical management in patients with COPD. This study 
investigated the relationship between time from hospital presentation to diagnosis of AHRF and in-
hospital mortality. 
Methods: Retrospective analysis of hospitalised COPD patients treated with a first episode of ward-
based NIV for AHRF at a large UK teaching hospital between 2004 and 2017. Data collected 
prospectively as part of NIV service evaluation. Multivariable logistic regression performed to 
identify predictors of in-hospital mortality.  
Results: In total, 547 unique patients were studied comprising 245 males (44.8%), median age 70.6 
years, median FEV1 % predicted 34%. Overall in-hospital mortality was 19% (n=104); median 
survival was 1.7 years. In univariate analysis, a longer time between hospital presentation to diagnosis 
of AHRF was associated with in-hospital mortality (median [IQR]: 8.7 [0.7-75.8] hours vs. 1.9 [0.3-
13.6] hours, p<0.0001). In multivariable logistic regression, significant predictors of in-hospital 
mortality were AHRF >24 hours after hospital presentation (odds ratio [95% CI]: 2.29 [1.33-3.95], 
p=0.003), pneumonia on admission (1.81 [1.07-3.08], p=0.027), increased age (1.10 [1.07-1.14], 
p<0.001) and NIV as ceiling of treatment (5.86 [2.87- 11.94], p<0.001). 
Conclusions: Hospitalised COPD patients with late presentation of AHRF, requiring acute ward-
based NIV, may have increased in-hospital mortality. These patients may benefit from closer 
monitoring and earlier specialist respiratory review.  
Keywords: chronic obstructive pulmonary disease; acute exacerbation; ward-based; non-invasive 
ventilation; acute hypercapnic respiratory failure; mortality.  
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Introduction 
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory conditions in 
the UK and the third leading cause of death worldwide [1-3]. Acute exacerbations of COPD 
(AECOPD) are common and a significant year-on-year increase in the rate of AECOPD has been seen 
in England [4]. Acute hypercapnic respiratory failure (AHRF) is a recognised complication in 
AECOPD and occurs in approximately 20% of hospitalised cases [5, 6]. Crucially, development of 
AHRF is associated with worse clinical outcomes including increased in-hospital mortality and post-
discharge mortality [5, 7]. 
Medical management of AHRF in AECOPD includes targeting oxygen saturation to 88-92% and 
administering intra-venous fluids, bronchodilators, steroids and antibiotics if clinically indicated [8-
10]. Non-invasive ventilation (NIV) is recommended for the treatment of AHRF when, following >60 
minutes of optimal medical management, the following criteria are met: pH <7.35 and arterial pCO2 
> 6.5 kPa [11, 12]. A recent systematic review and meta-analysis of randomised controlled trials 
found that use of NIV for the management of AHRF in AECOPD was associated with reductions in 
the risk of mortality and endotracheal intubation of 46% and 65% respectively [13].  
The survival benefits associated with NIV seen in ‘real life’ data obtained by the UK National COPD 
Resources and Outcomes Project (NCROP), British Thoracic Society (BTS) adult NIV audits and the 
National Confidential Enquiry into Patient Outcomes and Death (NCEPOD) have been less striking 
[6, 14, 15]. Of concern, there appears to be a group of patients with AECOPD who are admitted 
without AHRF but go on to develop AHRF later during their hospital admission. These patients have 
been reported to be at risk of worse outcomes, however the literature describing this group is limited. 
This study aimed to evaluate the relationship between time from hospital presentation to diagnosis of 
AHRF and in-hospital mortality in COPD patients treated with ward-based NIV. 
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Methods 
Study population 
This was a single centre, retrospective, observational cohort study. Patients with COPD undergoing a 
first episode of ward-based NIV for AHRF at a large teaching hospital in the West Midlands (UK) 
were prospectively enrolled into the NIV department registry between July 2004 to November 2017. 
The NIV service is run in a dedicated bay on a respiratory ward, with an acuity-based nursing staffing 
level scoring system (supplementary material section A), and daily senior specialist respiratory ward 
rounds, as well as a 7 day physiotherapy support service. Clinical diagnoses of COPD were confirmed 
with spirometry (FEV1/FVC ratio <0.7). In patients without spirometry, discharge letters, respiratory 
clinic letters, chest x-rays and computed tomography (CT) findings were reviewed to verify clinical 
diagnoses. Patients were selected for acute, ward-based NIV as per Trust protocol (supplementary 
material section B). 
Data collection 
A diagnosis of pneumonia was made by the attending clinician at the time of admission and was 
confirmed by chest x-rays review by a member of the research team. CT scans were reviewed for 
evidence of bronchiectasis. Arrival times at the emergency department (ED) were extracted from 
electronic records. Pre-NIV arterial blood gas results and time of AHRF diagnosis were identified 
from case notes and recorded prospectively by NIV physiotherapists. The primary outcome of interest 
was in-hospital mortality.  
Statistical analysis 
Data were analysed in STATA version 15 (StataCorp, Texas, USA). Non-parametric data were 
expressed as median [inter-quartile range] and were analysed using the Mann-Whitney U test. 
Categorical data were expressed as number (percentage) and were analysed using the Chi-Squared 
test. A p-value <0.05 was considered statistically significant. Prognostic variables that were 
statistically significant in univariate analysis were taken forward into a multivariable logistic 
regression model to identify predictors of in-hospital mortality. A cut-off value of 24 hours from 
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arrival in the ED to diagnosis of AHRF was used to dichotomise patients to enable comparison with 
the NCEPOD data [15]. Kaplan Meier curves were constructed to compare in-hospital mortality in 
patients with or without pneumonia and in patients stratified by length of time between hospital 
presentation to diagnosis of AHRF (≤24 hours vs. >24 hours). 
Results  
A total of 829 eligible NIV admissions secondary to AHRF were available with 153 patients being 
admitted multiple times during the study period. Ninety three patients (61%) were admitted twice and 
with the remainder admitted between 2 and 10 times with only 7% admitted more than 5 times over 
the study period (supplementary material section C). There were 547 unique patients who attended as 
first presentation for NIV with 104 (19%) experiencing in-hospital mortality. Characteristics of the 
study population are summarised in Table 1. Median survival following first admission for acute 
ward-based NIV was 1.7 [1.4-2.03] years (supplementary material section D). Survivor functions 
were calculated at predetermined timepoints to give an estimate of 1-year, 3-year and 5-year survival. 
One-year survival in this cohort was 58.6% [54.3-62.7%], 3-year survival was 33.8% [29.5-38.1%] 
and 5-year survival was 22.3% [18.1-26.6%]. 
Table 1. Participant characteristics split by primary endpoint (in-hospital mortality). 
 Median [IQR] or n (%)  
Characteristic Total (n=547) Died in hospital 
(n=104) 
Discharged 
(n=443) 
P value 
Age (years) 70.6 [63.78-78.13] 79.56 [71.89-84.69] 69.45 [62.5-75.61] <0.0001 
Male gender  245 (44.79) 44 (42.31) 201 (45.37) 0.572 
Pneumonia on admission 143 (27.66) 42 (42.86) 101 (24.11) <0.0001 
Bronchiectasis# 104 (26.4) 19 (26.39) 85 (26.4) 0.999 
FEV1 (litres)* 0.71 [0.54-0.96] 0.7 [0.5-0.9] 0.72 [0.55-0.98] 0.349 
FEV1 % predicted* 34 [26-43] 34 [27-46] 34 [25.55-43] 0.3501 
NIV ceiling of treatment 301 (55.03) 92 (88.46) 209 (47.18) <0.0001 
Pre-NIV pH 7.27 [7.21-7.3] 7.26 [7.2-7.3] 7.27 [7.22-7.31] 0.2065 
Pre-NIV pCO2 (kPa) 9.91 [8.43-11.5] 10.1 [8.56-11.8] 9.86 [8.4-11.4] 0.34 
Pre-NIV pO2 (kPa) 7.83 [6.73-9.49] 7.74 [6.67-9.3] 7.85 [6.74-9.51] 0.3809 
Arrival to AHRF (hours) 2.17 [0.32-19.93] 8.67 [0.69-75.83] 1.87 [0.25-13.58] <0.0001 
Arrival to AHRF >24 hours 124 (22.67) 41 (39.42) 83 (18.74) <0.0001 
AHRF to NIV (hours) 1.83 [1-3.67] 1.67 [1-3.6] 1.87 [0.25-13.58] 0.5204 
Duration of NIV (days) 5.07 [3.04-7.1] 3.04 [1.01-6.09] 5.07 [3.04-7.1] 0.0002 
Maximum IPAP (cmH2O) 16 [14-20] 17 [14-20] 16 [14-20] 0.1312 
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Maximum EPAP (cmH2O) 5 [4-6] 5 [4-6] 5 [4-6] 0.6958 
Maximum oxygen (litres/min) 5 [3-10] 7 [4-12] 5 [3-10] 0.0023 
Transferred to ICU 17 (3.11) 4 (3.85) 13 (2.93) 0.630 
Intubated 10 (1.83) 4 (3.85) 6 (1.36) 0.089 
Abbreviations: CT, computed tomography; FEV1, forced expiratory volume in one second; NIV, non-invasive 
ventilation; Arrival to AHRF, time from presentation to the emergency department to diagnosis of AHRF; 
AHRF to NIV, time from diagnosis of AHRF to application of NIV; IPAP, inspiratory positive airway pressure; 
EPAP, expiratory positive airway pressure; ICU, intensive care unit. #Bronchiectasis based on a total of 394 
patients with either CT available (n=338) or clinical diagnosis from patient records (n=56), *FEV1 based on 419 
patients with available spirometry. 
 
In univariate analysis, a longer time between hospital presentation to diagnosis of AHRF was 
associated with in-hospital mortality (8.7 [0.7-75.8] vs. 1.9 [0.3-13.6] hours, p<0.0001) and a higher 
proportion of patients with in-hospital mortality were diagnosed with AHRF >24 hours after 
presentation to hospital (41 [39.4%] vs. 83 [18.7%], p<0.0001). Long term median survival for those 
diagnosed with AHRF<24 hours post admission compared to AHRF>24 hours post admission 
differed (1.7 [95%CI 1.47-2.16] vs. 0.84 [95%CI  0.28-1.92] years, p=0.046).  
 
Patients with in-hospital mortality were also older (79.6 [71.9-84.7] vs. 69.5 [62.5-75.6] years, 
p<0.0001), had a higher rate of pneumonia on admission chest x-ray (42 [42.9%] vs. 101 [24.1%], 
p<0.0001), higher proportion with NIV as a ceiling of treatment (92 [88] [74%] vs. 209 [47%], 
p<0.0001), shorter duration of NIV (3.04 [1.01-6.09] days vs. 5.07 [3.04-7.1] days, p=0.0002) and a 
higher maximum oxygen flow during NIV (7 [4-12] L/min vs. 5 [3-10] L/min, p=0.0023). They also 
had a shorter duration of NIV (3.04 [1.01-6.09] days v’s 5.07 [3.04-7.1] days, p=0.0002) .There were 
no differences between groups in gender, rate of co-morbid bronchiectasis, FEV1, pre-NIV arterial 
blood gas result, time from diagnosis of AHRF to application of NIV, rate of transfer to ICU, 
intubation rate or maximum IPAP or EPAP achieved during NIV. 
In multivariable logistic regression, significant predictors of in-hospital mortality were AHRF >24 
hours after hospital presentation, pneumonia on admission, increased age and NIV as ceiling of 
treatment (Table 2). Kaplan Meier curves were constructed comparing in-hospital mortality in groups 
split by AHRF >24 hours after hospital presentation and pneumonia on admission (Figure 1). 
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Table 2. Multivariable logistic regression. 
Variable Odds Ratio Standard 
Error 
95% Confidence Interval P-value 
Lower Upper 
Arrival to AHRF >24 hours 2.29 0.64 1.33 3.95 p=0.003 
Pneumonia on admission 1.81 0.49 1.07 3.08 p=0.027 
Increased age 1.10 0.02 1.07 1.14 p<0.001 
NIV ceiling of treatment 5.86 2.13 2.87 11.94 p<0.001 
 
Figure 1. Kaplan Meier curves illustrating in-hospital mortality in patients stratified by AHRF >24 
hours after hospital presentation (A, log-rank: p=0.0001) and pneumonia on admission (B, log-rank: 
p=0.0002). 
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Discussion 
This study of COPD patients undergoing a first episode of acute ward-based NIV found that patients 
who presented with AHRF later during hospital admission experienced increased in-hospital 
mortality. This relationship persisted after adjustment for confounding factors in a multivariable 
model and remained the most significant independent predictor of in-hospital mortality. The inclusion 
of only patients at first presentation is due to the differences that have been identified previously in 
the literature and specifically in this cohort. This has including the more rapid progression from ED 
onto the NIV service of those who are on the second or later presentation, which presumably occurs 
due to their pre-identified risk factor of prior NIV, and proven previous efficacy of NIV treatment 
[16]. 
Prognostication in AECOPD is an important and evolving area [17]. The high mortality rate 
experienced by patients with AHRF necessitates careful identification of factors that predict poor 
outcome. NCEPOD found that patients initiated on NIV 24 hours after admission had greater in-
hospital mortality (55.6% vs. 25.1%). Prior to this, Roberts et al. [6] presented a large UK dataset of 
hospitalised COPD patients, of which 1077 patients had received acute NIV. The authors split patients 
into three groups, with different mortality rates, based on timing of acidosis: lowest pH on admission, 
acidotic on admission but a lower pH later and non-acidotic on admission but acidotic later (in-
hospital mortality rates: 19% vs. 26% vs. 39%, respectively). Our findings are therefore in-keeping 
with the data from Roberts et al. [6] and NCEPOD [15] but go further in describing the relationship 
between the timing of AHRF and risk of in-hospital mortality. In this study, we were able to ascertain 
independent predictors of in-hospital mortality by way of detailed individual patient data, enabling us 
to quantify the relationship between timing of AHRF and mortality. 
Reasons for later development of AHRF in COPD patients presenting to the ED are likely to be 
multifactorial. It is feasible that later diagnosis of AHRF may reflect a lack of patient response to 
initial medical treatment, indicating more severe acute illness. The inappropriate use of and control of 
supplementary oxygen in COPD has also been cited previously [18, 19]. A competing mechanism 
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would be that these patients represent a phenotype of AECOPD patients who, as part of the course of 
their disease, deteriorate later. These patients may represent a frail subgroup of patients, whom need 
careful monitoring and earlier input from respiratory specialists [20, 21]. It is possible that later 
development of acidosis may, in part, result from concurrent metabolic acidosis, due to competing 
pathophysiological mechanisms including acute kidney injury and hypovolaemic hypoperfusion of 
tissues. However, this mechanism would not warrant use of NIV as a treatment for acidosis, hence is 
less likely in our cohort where detailed case note review was able to adequately exclude this.  
Concerningly, a large proportion of patients in our cohort had concomitant pneumonia on admission 
chest x-ray and these patients had higher in-hospital mortality. This finding is in-keeping with the 
NCEPOD data which found that patients with pneumonia had higher in-hospital mortality (44.4% vs. 
24.8%). It is important to note that, in our study, >50% of patients had NIV as a ceiling of treatment. 
This may partly explain the high proportion of patients with concomitant pneumonia being treated 
with ward-based NIV, rather than being transferred to critical care. Moreover, a significantly higher 
proportion of patients who died in hospital had NIV as a ceiling of treatment (88% vs. 47%, 
p<0.0001). Those patients that died whilst in hospital were on NIV for a shorter period of time 
possibly reflecting more rapid clinical deterioration or poor tolerance of the treatment, with few other 
options available, and a shift to palliation. The latter is consistent with the high number of patients 
that were given NIV as a ceiling of treatment due to clinician’s perceptions about survival and futility 
of care. Further exploration of the impact of attitudes to commencing NIV and subsequent case 
management including palliative care, would require a prospective design with a mixed methods 
approach focussed on clinical decision making.  Attitudes toward death, and a feeling that ‘something 
must be tried’ even if it is likely to be futile may well be playing a part. 
The finding that very few patients were transferred to the ICU or were intubated, is in-keeping with 
national data [14]. As discussed, this may simply reflect a higher proportion of patients having NIV as 
a ceiling of treatment, however this may also reflect increased confidence and competence in the 
delivery of acute ward-based NIV, obtained over the past two decades [22]. A recent model of care 
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and economic assessment between differing settings (ward based, high dependency unit and ICU) for 
the provision of NIV in treating AHRF demonstrated the ward environment produced equivalent 
clinical outcomes at a lower cost per patient [23] again supporting the delivery of service in this 
environment. 
The higher mortality rate seen in patients with concomitant pneumonia highlights the importance of 
the NCEPOD recommendation that “Early senior review and escalation planning is essential to ensure 
these patients receive appropriate treatment in the correct location.”[15]. Carlucci et al [24] highlight 
important changes in the presentation and severity of patients requiring NIV over an 8 year period and 
it is accepted that this observational study was undertaken over a prolonged period of time, 2004-
2017. Previously published data by Trethewey et al [25] compared two cohorts of patients between 
2004-2010 and 2013-2017 and observed patients with more severe presentations of AHRF, yet stable 
in-hospital mortality, alongside a decline in the duration of NIV treatment and hospital length of stay 
for survivors implying that this may be a factor in our cohort. To address this we conducted a 
sensitivity analysis in which an extra variable of ‘admission year’ was added to the model 
(supplementary material section E); this suggested that year of admission for NIV did not impact the 
odds ratio for in-hospital mortality in this cohort or offer improvement to the fit of the model. 
The global burden of COPD is high and appears to be increasing [2]. Importantly, as part of the 
natural course of the disease, a significant proportion of patients will experience an AECOPD [26]. A 
key finding from the landmark Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
Endpoints (ECLIPSE) study was that, during 3-year follow-up, 31% of patients experienced at least 
one AECOPD requiring hospital admission [27]. Crucially, around 20% of hospitalised patients with 
AECOPD will develop AHRF and this is associated with a significant mortality rate [5, 6]. The 
overall in-hospital mortality rate of 19% observed in our cohort is higher than in the original 
randomised controlled trial advocating the use of NIV in AECOPD [28] but markedly lower than the 
data presented by NCEPOD (25.1%) and NCROP (25%) [6, 15]. It is possible that the lower overall 
mortality seen in our cohort may, in part, be due to the early adoption and development of an acute, 
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ward-based NIV service and implementation of BTS-recommended NIV leadership at our institution 
[29, 30]. However, it is important to note that median survival in this patient cohort was poor, which 
is in-keeping with data from a recent, large, retrospective observational cohort study of COPD 
patients aged ≥65 years, derived from a US Medicare database by Lindenauer et al. [7]. The authors 
observed a 1-year mortality rate of 41.8% in COPD patients who survived to hospital discharge 
following admission for acute NIV between 2008-2014. Taken together, these findings highlight the 
poor long-term prognosis in COPD patients treated with acute NIV. Survivors of acute NIV should 
therefore have future treatment plans discussed and documented, including advance-care planning and 
patient preferences regarding emergency care decisions in the likely event of future clinical 
deterioration. Despite international consensus regarding the importance of advance-care planning in 
patients with severe COPD, barriers to this process persist [31]. A qualitative study by Smith et al. 
[32] demonstrated that although many survivors of acute NIV have contemplated their mortality and 
preferences regarding future treatment and resuscitation decisions, many do not discuss these 
preferences with healthcare professionals. Further research regarding optimal methods and timing of 
advance-care planning discussions is needed to improve this important aspect of care in survivors of 
acute NIV. 
Strengths and Limitations: 
Key strengths of this study include the large cohort size, which is significantly larger that the COPD 
cohort analysed as part of the NCEPOD report. Additional strengths of this study include the long 
observation period and the reliability of clinical diagnoses of COPD utilising spirometry, CT findings, 
chest x-ray reports, clinical letters and discharge summaries. The findings of this study are limited by 
the uncontrolled, retrospective observational cohort design. Reporting of initial ‘arrival in ED’ times 
relied on electronic input of data by triaging clinicians, which may be subject to inaccuracy. We were 
unable to replicate data by Roberts et al [6] in reporting rates of ABG’s performed at the first point of 
care in ED. Whilst this study cannot rule out a delay in an appropriate and timely ABG on admission 
to ED, COPD patients admitted to our ED would normally have ABG done as an initial triage 
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screening that would be expected to have been completed within 4 hours of documented admission. A 
prospective, observational cohort study, with serial ABGs, is required to confirm these findings.  
Whilst chest x-ray review was undertaken for confirmation of a pneumonia diagnosis these were not 
further classified (eg lobar, diffuse) in the scope of this work. A future research plan is to review and 
classify these and review any associated microbiology results available.  It is accepted that patient 
BMI may affect the success of NIV, however this was not reliably recorded in the clinical case notes 
and therefore is a limitation of this study. 
 
Conclusions:  
In summary, hospitalised COPD patients with late presentation of AHRF, requiring acute ward-based 
NIV, may have increased in-hospital mortality. These patients may benefit from closer monitoring 
and earlier specialist respiratory review. Further research is required to elucidate clinically relevant 
time points and their relationship with mortality and highlight deficiencies in the timeliness of clinical 
diagnostic testing to inform clinical decision making. 
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Manuscript Highlights: YRMED-D-19-00010 
Late presentation of acute hypercapnic respiratory failure carries a high mortality risk 
in COPD patients treated with ward-based NIV 
• Increased in-hospital mortality in COPD patients with AHRF >24 hours post 
admission 
• >50% of patients started on ward-based NIV had this as ceiling of care 
• Pneumonia presents increased odds of in-hospital mortality with ward-based NIV 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Declaration of interests 
 
☐ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☒The authors declare the following financial interests/personal relationships which may be considered 
as potential competing interests:  
 
 
 
 
 
SPT and JM report no competing interests. AMT reports grants from Grifols biotherapeutics, grants from 
Alpha 1 Foundation, personal fees from CSL Behring, grants and non-financial support from Arrowhead 
Inc, outside the submitted work. RM reports non-financial support from ResMed, non-financial support 
from Breas and non-financial support from B&D electromedical outside the submitted work. RGE is 
supported by a Clinical Doctoral Research Fellowship (CDRF-2014-05-044), funded by the National 
Institute for Health Research (NIHR)and Health Education England (HEE), outside of the scope of this work. 
The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, HEE or the 
Department of Health. 
